Performance Comparison of Microfluidic and Immunomagnetic Platforms for Pancreatic CTC Enrichment
November 15, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Eliquis
Synonyms :
apixaban
Class :
Anticoagulants, Cardiovascular, Factor Xa Inhibitors
Brand Name :
Eliquis
Synonyms :
apixaban
Class :
Anticoagulants, Cardiovascular, Factor Xa Inhibitors
Dosage forms & StrengthsÂ
TabletÂ
5mgÂ
2.5mgÂ
Safety and efficacy not established.Â
Refer to adult dosingÂ
it may enhance the adverse/toxic effect of apixaban
it may enhance the adverse/toxic effect of apixaban
it may enhance the adverse/toxic effect of apixaban
it may enhance the adverse/toxic effect of apixaban
it may enhance the adverse/toxic effect of apixaban
may increase the adverse effect of nonsteroidal anti-inflammatory agents
may increase the adverse effect of nonsteroidal anti-inflammatory agents
may increase the adverse effect of nonsteroidal anti-inflammatory agents
may increase the adverse effect of nonsteroidal anti-inflammatory agents
may increase the adverse effect of nonsteroidal anti-inflammatory agents
may diminish the serum concentration when combined with apixaban
may diminish the serum concentration when combined with apixaban
may diminish the serum concentration when combined with apixaban
may diminish the serum concentration when combined with apixaban
may diminish the serum concentration when combined with apixaban
apixaban: it may enhance the toxic effect of Anti-Inflammatory Agents
apixaban: it may enhance the toxic effect of Anti-Inflammatory Agents
aspirin, chlorpheniramine, and phenylephrine
apixaban: it may enhance the toxic effect of Anti-Inflammatory Agents
apixaban: it may enhance the toxic effect of Anti-Inflammatory Agents
apixaban: it may enhance the toxic effect of Anti-Inflammatory Agents
may increase the anti coagulant activity
may enhance the serum concentration of P-glycoprotein/ABCB 1 inhibitors
may increase the toxic effect of anti-platelet agents
may increase the toxic effect of aspirin
may have an increasingly adverse effect when combined with apixaban
may increase the toxic effect of nonsteroidal anti-inflammatory agents
may diminish the serum concentration of CYP3A4 Inducers
it increases the effect of anticoagulants
it increases the effect of anticoagulants
it increases the effect of anticoagulants
it increases the effect of anticoagulants
it increases the effect of anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
It may diminish the effect when combined with phenobarbital by affecting the intestinal/hepatic enzyme CYP3A4
When both drugs are combined, there may be an increased risk of bleeding and sometimes fatal hemorrhage  
CYP3A strong enhancers of the small intestine may reduce the bioavailability of apixaban
when combined may increase anticoagulation
when combined may increase anticoagulation
may increase the anti-coagulant action of anti-coagulants
anticoagulants increase the effect of anticoagulation of rivaroxaban
it increases the effect of anticoagulants
may have an increased anticoagulant effect when combined with anticoagulants
may have an increased thrombogenic effect when combined with anti- coagulant inhibitor complex
valproate decreases the efficacy of apixaban
may have an increasingly adverse effect when combined with Apixaban
may have an increasingly adverse effect when combined with Apixaban
may have an increasingly adverse effect when combined with Apixaban
may have an increasingly adverse effect when combined with Apixaban
may have an increasingly adverse effect when combined with Apixaban
other antiplatelet agents increase the toxicity of apixaban
other antiplatelet agents increase the toxicity of apixaban
may decrease the therapeutic effect when combined with anticoagulants
may decrease the therapeutic effect when combined with anticoagulants
may decrease the therapeutic effect when combined with anticoagulants
may decrease the therapeutic effect when combined with anticoagulants
may decrease the therapeutic effect when combined with anticoagulants
Combining apixaban with pranlukast may cause a reduction in the apixaban metabolism
Combining tegafur with apixaban can reduce tegafur’s metabolism
When apixaban is used together with sertraline, the risk or seriousness of bleeding may be enhanced
When dexrabeprazole and apixaban is used together, this leads to reduction in the dexrabeprazole’s metabolism
When apixaban is used together with fluconazole, this leads to reduction in the apixaban metabolism
When indisulam is used together with apixaban, this leads to a reduction in apixaban metabolism
apixaban: it may increase the anticoagulant effect of agents with Antiplatelet Properties
apixaban: it may increase the anticoagulant effect of agents with Antiplatelet Properties
apixaban: it may decrease the therapeutic efficacy of soyabean oil
apixaban: it may decrease the metabolism of cerivastatin
when both drugs are combined, there may be an increased risk or severity of adverse effects  
the effect of apixaban is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
may increase the anti-coagulant effect of antiplatelet agents
may increase the anticoagulant effect of anticoagulants
may enhance the anticoagulant effect
may increase the anticoagulant effect of pentosan polysulfate sodium
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the effect of anticoagulant activity
may increase the effect of anticoagulant activity
may increase the effect of anticoagulant activity
may increase the effect of anticoagulant activity
may increase the effect of anticoagulant activity
severity of hemorrhage and bleeding can be raised if bumadizone is taken with apixaban
The anticoagulant effects of ancord may be enhanced when administered concomitantly with other anticoagulants
the serum levels of apixaban may be increased
the risk of bleeding may be increased
the rate of metabolism of apixaban may be reduced
the serum concentration of digitoxin can be increased when it is combined with apixaban
it may increase the anticoagulant effect
Actions and Spectrum:Â
apixaban is a medication that belongs to a class of drugs known as direct oral anticoagulants (DOACs). It acts by inhibiting a clotting factor called Factor Xa, which prevents the formation of blood clots.Â
The action of apixaban is to decrease the possibility of blood clots and stroke in people who have certain medical conditions, such as atrial fibrillation, deep vein thrombosis, or pulmonary embolism. It is also generally used to prevent blood clots in patients who have undergone hip or knee replacement surgery.Â
apixaban has a narrow therapeutic spectrum, which means that the dose needs to be carefully monitored and adjusted to avoid both bleeding and clotting complications. Therefore, patients taking apixaban should be closely monitored by their healthcare provider to ensure that they are receiving the appropriate dose.Â
Frequency definedÂ
Bleeding from Averroes StudyÂ
Intracranial (0.34%, aspirin 0.35%)Â
Major (1.41%, aspirin 0.92%)Â
Fatal (0.16%, aspirin 0.16%)Â
Bleeding from Aristotle StudyÂ
Major (2.13%, warfarin 3.09%)Â
Nonmajor (2.08%, warfarin 3.0%)Â
Gastrointestinal (0.83%, warfarin 0.93%)Â
Intracranial (0.33%, warfarin 0.82%)Â
Fatal (0.06%, warfarin 0.24%)Â
Intraocular (0.06%, warfarin 0.14%)Â
<1%Â
SyncopeÂ
Hypersensitivity reactions such as allergic edema, skin rashÂ
Black Box Warning:Â
apixaban has a black box warning regarding the risk of discontinuation of therapy. Abrupt discontinuation of apixaban increases the risk of thrombotic events (blood clots), so it is important that patients do not stop taking this medication without consulting their healthcare provider.Â
apixaban also has a black box warning regarding the increased risk of spinal/epidural hematoma in patients undergoing spinal procedures or receiving spinal anesthesia while taking the medication.
This may result in long-term or permanent paralysis, and patients should be carefully monitored for signs of bleeding during and after these procedures.Â
Contraindication/Caution:Â
ContraindicationÂ
There are several contraindications to the use of apixaban, which means that it should not be prescribed or taken by individuals who have certain medical conditions or are taking certain medications. These contraindications include:Â
CautionÂ
There are several cautions to be aware of when using apixaban, which means that the medication should be used with caution and careful monitoring in individuals who have certain medical conditions or are taking certain medications. These cautions include:Â
Pregnancy consideration:Â Â
AU TGA pregnancy category: C
US FDA pregnancy category: Not assigned.Â
Lactation:  Â
Excreted into human milk is Not known. Â
Breastfeeding warnings:Â Â
Pregnancy category:Â
Pharmacology:Â
apixaban is a direct oral anticoagulant that belongs to class of medications known as factor Xa inhibitors. It works by selectively inhibiting the activity of factor Xa, a key enzyme in the blood clotting cascade. By inhibiting factor Xa, apixaban stops the build up of blood clots and decreases the risk of thromboembolic events.Â
Pharmacodynamics:Â
Mechanism of action: factor Xa inhibitor that selectively and reversibly blocks the active site of factor Xa without requiring antithrombin III for activity. It inhibits the free and clot-bound factor Xa as well as prothrombinase activity. Although it does not have a direct effect on platelet aggregation, it indirectly inhibits platelet aggregation that is induced by thrombin. The activation of the factor X to factor Xa is necessary for the blood coagulation cascade, and it occurs via the intrinsic and extrinsic pathways, which have a central role in this process.Â
Pharmacokinetics:Â
AbsorptionÂ
The substance exhibits a bioavailability characterized by prolonged absorption, it takes a longer time to be absorbed into the bloodstream. The peak plasma concentration of this substance is reached 3 to 4 hours after administration.Â
DistributionÂ
It is highly bound to proteins, with 87% of it being bound. It has a volume of distribution at steady state (Vdss) of 21 L, indicating that it is distributed throughout the body beyond the plasma volume.Â
MetabolismÂ
The substance in question is primarily metabolized by the enzyme CYP3A4, with minor contributions from CYP1A2, 2C8, 2C9, 2C19, and 2J2. The major sites of biotransformation are O-demethylation and hydroxylation at the 3-oxopirperidinyl moiety. There are no active circulating metabolites of this substance. It is a substrate of both P-glycoprotein and breast cancer resistance protein (BCRP), which are transporters that play a role in the absorption and disposition of many drugs.Â
Elimination and ExcretionÂ
It has a half-life of 5-6 hours (dominant) and an apparent half-life of 12 hours with repeated dosing. It is not dialyzable, meaning it cannot be removed from the body through dialysis. Renal clearance accounts for 27% of the total clearance of this substance. It is primarily excreted as metabolites, with 25% eliminated in both urine and feces. Biliary and direct intestinal excretion also contribute to elimination in feces.Â
Administration:Â
Oral administrationÂ
apixaban is an oral medication that is usually taken twice daily, with or without food. The recommended dose of apixaban may vary depending on the patient’s medical condition, age, weight, renal function, and other factors.Â
It is important that patients take apixaban exactly as prescribed by their healthcare provider. Â
If a dose is missed, it is recommended to take it as soon as possible. However, if the next scheduled dose is missed, it should be skipped and the following dose should be taken at the appropriate time. It is important to avoid taking a double dose of the medication to compensate for the missed dose.Â
Patients should not double the dose to make up for a missed dose or take more than the prescribed dose unless instructed to do so by their healthcare provider.Â
Patients taking apixaban should also avoid any activities that may increase the risk of bleeding or injury, such as contact sports or heavy lifting, unless otherwise instructed by their healthcare provider.Â
It is important that patients do not discontinue apixaban therapy without consulting their healthcare provider, as abrupt discontinuation of the medication can increase the risk of blood clots and other complications.Â
As always, patients should discuss any questions or concerns about the administration of apixaban with their healthcare provider.Â
Patient information leafletÂ
Generic Name: apixaban Â
Pronounced: [ a-PIX-a-ban ]Â
Why do we use apixaban?Â
apixaban is an anticoagulant medication that is used to prevent and treat blood clots in various medical conditions. Some of the common uses of apixaban include:Â
apixaban works by inhibiting a specific clotting factor in the blood called factor Xa, which is involved in the formation of blood clots. By blocking factor Xa, apixaban helps to prevent the formation of new blood clots and reduces the risk of complications associated with blood clots, such as stroke or pulmonary embolism.Â
It is important that patients taking apixaban are aware of potential risks and side effects of the medication and should always discuss any questions or concerns with their healthcare provider.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
